Overview
MYGN market data
Price History
MYGN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.95 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.61 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.53 – $8.59 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $531.7 · P/B 1.56 · P/S 0.64.
Company news
Myriad Genetics Announces Expanded Availability Of Precise MRD To Patients Undergoing Treatment And Surveillance For Breast, Colorectal And Renal CancersBenzinga · Jun 23, 2026, 1:15 PM
8-K filing — MYRIAD GENETICS INC (MYGN)SEC EDGAR · Jun 23, 2026, 12:32 PM
Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS InsiderGlobenewswire Inc · Jun 19, 2026, 11:00 AM
Myriad Genetics Launches Combined Genomics And AI-Backed Prostate Cancer TestBenzinga · May 26, 2026, 8:11 PM
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her LifeGlobenewswire Inc · May 15, 2026, 3:15 PM
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsightGlobenewswire Inc · May 14, 2026, 5:15 PM